www.pneumonologia.viamedica.pl PRACA ORYGINALNA

The value of topotecan in the second-line treatment of small-cell lung cancer. Preliminary report Introduction: Small-cell lung cancer (SCLC) is a highly aggressive malignancy with a high potential for growth and spread. Responses to first-line treatment are common but generally short-lived. Nearly all patients with extensive disease and most with limited disease relapse. The choice of second-line treatment depends on many factors, including previous treatment, previous response, time from completion of previous treatment to progression, and performance status. The most common chemotherapy regimen used in the second-line setting is the one which has led to long-term remission in the first-lin